EU fines six for pay-for-delay

Share this article:

The European Union is fining drugmakers over efforts to keep generics of the blood-pressure drug perindopril off the market.

Bloomberg reports that the EU has fined six drugmakers, including brand owner Les Laboratories Servier ($451 million) and generic maker Teva ($21 million), over the pay-for-delay strategy which extended the brand's hold on the marketplace.

Bloomberg says the EU's accusations against Servier included making agreements with generics makers to keep generics out of pharmacies and acquiring competing technologies.

Krka Group, Mylan Laboratories, Unichem Laboratories and Lupin Ltd., were also fined.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.